Abstract
Summary
LPI (LP Information)' newest research report, the “Generic Medicine Industry Forecast” looks at past sales and reviews total world Generic Medicine sales in 2022, providing a comprehensive analysis by region and market sector of projected Generic Medicine sales for 2023 through 2029. With Generic Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Generic Medicine industry.
This Insight Report provides a comprehensive analysis of the global Generic Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Generic Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Generic Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Generic Medicine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Generic Medicine.
The global Generic Medicine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Generic Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Generic Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Generic Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Generic Medicine players cover Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Generic Medicine market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Simple Generic Drugs
Super Generic Drugs
Biosimilars
By Application:
CNS
Cardiovascular
Respiratory
Rheumatology
Diabetes
Oncology
Segmentation by application
CNS
Cardiovascular
Respiratory
Rheumatology
Diabetes
Oncology
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
This Insight Report provides a comprehensive analysis of the global Generic Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Generic Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Generic Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Generic Medicine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Generic Medicine.
The global Generic Medicine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Generic Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Generic Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Generic Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Generic Medicine players cover Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Generic Medicine market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Simple Generic Drugs
Super Generic Drugs
Biosimilars
By Application:
CNS
Cardiovascular
Respiratory
Rheumatology
Diabetes
Oncology
Segmentation by application
CNS
Cardiovascular
Respiratory
Rheumatology
Diabetes
Oncology
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Generic Medicine Market Size 2018-2029
2.1.2 Generic Medicine Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Generic Medicine Segment by Type
2.2.1 Simple Generic Drugs
2.2.2 Super Generic Drugs
2.2.3 Biosimilars
2.2.4 By Application:
2.2.5 CNS
2.2.6 Cardiovascular
2.2.7 Respiratory
2.2.8 Rheumatology
2.2.9 Diabetes
2.2.10 Oncology
2.3 Generic Medicine Market Size by Type
2.3.1 Generic Medicine Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Generic Medicine Market Size Market Share by Type (2018-2023)
2.4 Generic Medicine Segment by Application
2.4.1 CNS
2.4.2 Cardiovascular
2.4.3 Respiratory
2.4.4 Rheumatology
2.4.5 Diabetes
2.4.6 Oncology
2.4.7 Others
2.5 Generic Medicine Market Size by Application
2.5.1 Generic Medicine Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Generic Medicine Market Size Market Share by Application (2018-2023)
3 Generic Medicine Market Size by Player
3.1 Generic Medicine Market Size Market Share by Players
3.1.1 Global Generic Medicine Revenue by Players (2018-2023)
3.1.2 Global Generic Medicine Revenue Market Share by Players (2018-2023)
3.2 Global Generic Medicine Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Generic Medicine by Regions
4.1 Generic Medicine Market Size by Regions (2018-2023)
4.2 Americas Generic Medicine Market Size Growth (2018-2023)
4.3 APAC Generic Medicine Market Size Growth (2018-2023)
4.4 Europe Generic Medicine Market Size Growth (2018-2023)
4.5 Middle East & Africa Generic Medicine Market Size Growth (2018-2023)
5 Americas
5.1 Americas Generic Medicine Market Size by Country (2018-2023)
5.2 Americas Generic Medicine Market Size by Type (2018-2023)
5.3 Americas Generic Medicine Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Generic Medicine Market Size by Region (2018-2023)
6.2 APAC Generic Medicine Market Size by Type (2018-2023)
6.3 APAC Generic Medicine Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Generic Medicine by Country (2018-2023)
7.2 Europe Generic Medicine Market Size by Type (2018-2023)
7.3 Europe Generic Medicine Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Generic Medicine by Region (2018-2023)
8.2 Middle East & Africa Generic Medicine Market Size by Type (2018-2023)
8.3 Middle East & Africa Generic Medicine Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Generic Medicine Market Forecast
10.1 Global Generic Medicine Forecast by Regions (2024-2029)
10.1.1 Global Generic Medicine Forecast by Regions (2024-2029)
10.1.2 Americas Generic Medicine Forecast
10.1.3 APAC Generic Medicine Forecast
10.1.4 Europe Generic Medicine Forecast
10.1.5 Middle East & Africa Generic Medicine Forecast
10.2 Americas Generic Medicine Forecast by Country (2024-2029)
10.2.1 United States Generic Medicine Market Forecast
10.2.2 Canada Generic Medicine Market Forecast
10.2.3 Mexico Generic Medicine Market Forecast
10.2.4 Brazil Generic Medicine Market Forecast
10.3 APAC Generic Medicine Forecast by Region (2024-2029)
10.3.1 China Generic Medicine Market Forecast
10.3.2 Japan Generic Medicine Market Forecast
10.3.3 Korea Generic Medicine Market Forecast
10.3.4 Southeast Asia Generic Medicine Market Forecast
10.3.5 India Generic Medicine Market Forecast
10.3.6 Australia Generic Medicine Market Forecast
10.4 Europe Generic Medicine Forecast by Country (2024-2029)
10.4.1 Germany Generic Medicine Market Forecast
10.4.2 France Generic Medicine Market Forecast
10.4.3 UK Generic Medicine Market Forecast
10.4.4 Italy Generic Medicine Market Forecast
10.4.5 Russia Generic Medicine Market Forecast
10.5 Middle East & Africa Generic Medicine Forecast by Region (2024-2029)
10.5.1 Egypt Generic Medicine Market Forecast
10.5.2 South Africa Generic Medicine Market Forecast
10.5.3 Israel Generic Medicine Market Forecast
10.5.4 Turkey Generic Medicine Market Forecast
10.5.5 GCC Countries Generic Medicine Market Forecast
10.6 Global Generic Medicine Forecast by Type (2024-2029)
10.7 Global Generic Medicine Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Teva
11.1.1 Teva Company Information
11.1.2 Teva Generic Medicine Product Offered
11.1.3 Teva Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Teva Main Business Overview
11.1.5 Teva Latest Developments
11.2 Novartis - Sandoz
11.2.1 Novartis - Sandoz Company Information
11.2.2 Novartis - Sandoz Generic Medicine Product Offered
11.2.3 Novartis - Sandoz Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Novartis - Sandoz Main Business Overview
11.2.5 Novartis - Sandoz Latest Developments
11.3 Mylan
11.3.1 Mylan Company Information
11.3.2 Mylan Generic Medicine Product Offered
11.3.3 Mylan Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Mylan Main Business Overview
11.3.5 Mylan Latest Developments
11.4 Sun Pharmaceutical
11.4.1 Sun Pharmaceutical Company Information
11.4.2 Sun Pharmaceutical Generic Medicine Product Offered
11.4.3 Sun Pharmaceutical Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Sun Pharmaceutical Main Business Overview
11.4.5 Sun Pharmaceutical Latest Developments
11.5 Aspen
11.5.1 Aspen Company Information
11.5.2 Aspen Generic Medicine Product Offered
11.5.3 Aspen Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Aspen Main Business Overview
11.5.5 Aspen Latest Developments
11.6 Fresenius Kabi
11.6.1 Fresenius Kabi Company Information
11.6.2 Fresenius Kabi Generic Medicine Product Offered
11.6.3 Fresenius Kabi Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Fresenius Kabi Main Business Overview
11.6.5 Fresenius Kabi Latest Developments
11.7 Pfizer (Hospira)
11.7.1 Pfizer (Hospira) Company Information
11.7.2 Pfizer (Hospira) Generic Medicine Product Offered
11.7.3 Pfizer (Hospira) Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Pfizer (Hospira) Main Business Overview
11.7.5 Pfizer (Hospira) Latest Developments
11.8 Sanofi
11.8.1 Sanofi Company Information
11.8.2 Sanofi Generic Medicine Product Offered
11.8.3 Sanofi Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Sanofi Main Business Overview
11.8.5 Sanofi Latest Developments
11.9 Aurobindo
11.9.1 Aurobindo Company Information
11.9.2 Aurobindo Generic Medicine Product Offered
11.9.3 Aurobindo Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Aurobindo Main Business Overview
11.9.5 Aurobindo Latest Developments
11.10 Lupin
11.10.1 Lupin Company Information
11.10.2 Lupin Generic Medicine Product Offered
11.10.3 Lupin Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Lupin Main Business Overview
11.10.5 Lupin Latest Developments
11.11 Dr. Reddy's
11.11.1 Dr. Reddy's Company Information
11.11.2 Dr. Reddy's Generic Medicine Product Offered
11.11.3 Dr. Reddy's Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Dr. Reddy's Main Business Overview
11.11.5 Dr. Reddy's Latest Developments
11.12 Apotex
11.12.1 Apotex Company Information
11.12.2 Apotex Generic Medicine Product Offered
11.12.3 Apotex Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Apotex Main Business Overview
11.12.5 Apotex Latest Developments
11.13 Cipla
11.13.1 Cipla Company Information
11.13.2 Cipla Generic Medicine Product Offered
11.13.3 Cipla Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Cipla Main Business Overview
11.13.5 Cipla Latest Developments
11.14 ENDO (Par Pharmaceutical)
11.14.1 ENDO (Par Pharmaceutical) Company Information
11.14.2 ENDO (Par Pharmaceutical) Generic Medicine Product Offered
11.14.3 ENDO (Par Pharmaceutical) Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 ENDO (Par Pharmaceutical) Main Business Overview
11.14.5 ENDO (Par Pharmaceutical) Latest Developments
11.15 Stada Arzneimittel
11.15.1 Stada Arzneimittel Company Information
11.15.2 Stada Arzneimittel Generic Medicine Product Offered
11.15.3 Stada Arzneimittel Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Stada Arzneimittel Main Business Overview
11.15.5 Stada Arzneimittel Latest Developments
11.16 Krka Group
11.16.1 Krka Group Company Information
11.16.2 Krka Group Generic Medicine Product Offered
11.16.3 Krka Group Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Krka Group Main Business Overview
11.16.5 Krka Group Latest Developments
11.17 Nichi-Iko Pharmaceutical
11.17.1 Nichi-Iko Pharmaceutical Company Information
11.17.2 Nichi-Iko Pharmaceutical Generic Medicine Product Offered
11.17.3 Nichi-Iko Pharmaceutical Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Nichi-Iko Pharmaceutical Main Business Overview
11.17.5 Nichi-Iko Pharmaceutical Latest Developments
11.18 Valeant
11.18.1 Valeant Company Information
11.18.2 Valeant Generic Medicine Product Offered
11.18.3 Valeant Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Valeant Main Business Overview
11.18.5 Valeant Latest Developments
11.19 Zydus Cadila
11.19.1 Zydus Cadila Company Information
11.19.2 Zydus Cadila Generic Medicine Product Offered
11.19.3 Zydus Cadila Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Zydus Cadila Main Business Overview
11.19.5 Zydus Cadila Latest Developments
11.20 Hikma
11.20.1 Hikma Company Information
11.20.2 Hikma Generic Medicine Product Offered
11.20.3 Hikma Generic Medicine Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Hikma Main Business Overview
11.20.5 Hikma Latest Developments
12 Research Findings and Conclusion